Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bacardi Climbs to #32 Among the World’s Top Companies for Women8.10.2026 15:11:00 EEST | Press release
Bacardi Limited has climbed to #32 on the Forbes list of the World’s Top Companies for Women 2026, rising from #60 the previous year and earning a place on the prestigious global ranking for the fifth consecutive year. The family-owned company is the highest-ranked spirits company on this year’s list and ranks #2 in the “Food, Soft Beverages, Alcohol & Tobacco” category. The recognition reflects a continued commitment to creating opportunities, championing career development and cultivating a workplace where people feel valued, empowered and able to do their best work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008127263/en/ Bacardi celebrates being the highest-ranked spirits company in the Forbes World's Top Companies for Women 2026. “The most meaningful measure of our progress is seeing talented women choose to join Bacardi, build their careers here and advance into leadership roles,” says Nicole Zukowski, Chief Sup
SLB Awarded Digital Drilling Contract by TotalEnergies8.10.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced a 15-year agreement with TotalEnergies to use the DrillPlan™ coherent well planning and engineering solutions. The agreement will support TotalEnergies’ transition to a digital planning environment, connecting subsurface insights with well planning and engineering. Enabled by SLB’s DrillPlan solutions and the expertise of both companies, the agreement marks a significant step in the companies’ digital collaboration and reflects a broader shift across the industry as operators move toward scalable, interoperable digital platforms to improve engineering and well construction execution. The DrillPlan solutions will enable TotalEnergies to streamline well design and engineering activities by integrating offset well data, trajectory designs, casing and completion inputs, and planning assumptions used throughout the well construction process, enabling cross-functional teams to work from a common foundation of data, plans and as
Gaétane Baudry Appointed Senior Vice President/Global General Manager, Bobbi Brown8.10.2026 15:00:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Gaétane Baudry as Senior Vice President/Global General Manager, Bobbi Brown, effective October 8, 2026. Based in New York, she will report to Lisa Sequino, Global President, Makeup Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008525584/en/ Gaétane Baudry In this role, Gaétane will lead Bobbi Brown’s global strategy and continued evolution, strengthening the brand’s distinctive equity, advancing innovation and creativity, and deepening consumer engagement around the world. “Gaétane is an inspiring and highly collaborative leader who brings experience, energy and a strong focus on execution,” said Lisa Sequino, Global President, Makeup Brands. “Her global brand-building record, strong commercial leadership and passion for creating meaningful consumer experiences will be invaluable as Bobbi Brown builds on its unique brand equity focused
Adtran launches Mosaic One Agents to help teams easily scale operations8.10.2026 15:00:00 EEST | Press release
Adtran today launched Mosaic One Agents, a suite of AI agents designed to help organizations scale expertise across network management, customer care and business operations. Built on Mosaic One Fabric, it gives role-based agent teams access to data from Adtran and third-party networks, enabling them to investigate issues, coordinate work across teams and drive issues through to resolution. By handling time-consuming investigation, coordination and process tasks, Mosaic One Agents helps people resolve issues faster, extend their expertise across more workflows and retain control of critical network and business actions. “When something goes wrong, experienced people become a scarce resource. Every organization needs enough of them to understand what’s happening, coordinate the response, keep customers informed and get every issue resolved. During a major outage, there are never enough experts to do it all. Mosaic One Agents changes that,” said Philip Bednarz, GM of software platform at
The LYCRA Company to Spotlight Renewable LYCRA ® Fiber and Textile-to-Textile Circularity at Textile Exchange Conference 20268.10.2026 15:00:00 EEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel and personal care industries, will showcase Renewable LYCRA® fiber and its work to advance textile-to-textile recycling at Textile Exchange Conference 2026. The conference takes place October 12–16, at the Vancouver Convention Centre in Vancouver, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008178765/en/ At the Textile Exchange Conference 2026, The LYCRA Company will showcase Renewable LYCRA® fiber and its progress in advancing textile-to-textile recycling. This year's theme, "The Implementation Era," focuses on scaling what works across businesses, supply systems, and landscapes. At the conference, The LYCRA Company will highlight its work with partners across the value chain, helping to shape the future for textiles through renewable fiber solutions, circular innovation, and strategic industry partnerships. “Bringing more rec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom